Lv4
718 积分 2024-04-28 加入
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials
24天前
已完结
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction
24天前
已完结
Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates
30天前
已完结
Strategy for streamlining antibody–drug conjugate pharmacokinetic assays
1个月前
已完结
Simple quantitative haemolytic microassay for determination of complement alternative pathway activation (AP50)
4个月前
已完结
Progress and promise of pharmacodynamic biomarkers: novel strategies and assay considerations in drug development
5个月前
已完结
Accurate quantification of anti-drug antibodies against each unique Fab of a bispecific antibody using an ECL bridging assay
7个月前
已完结
Immunogenicity assay supporting clinical development of RGB-19, a proposed biosimilar to RoActemra®
7个月前
已完结
Streamlined neutralizing antibody assay development: overcoming serum interference, utilization of DOE and automation
7个月前
已完结
CD25: A potential tumor therapeutic target
9个月前
已完结
皖公网安备34019202002308
